Estamos no ar no !
Saiba mais
CYAD
Celyad Oncology SA American Depositary Shares
Deslistada
CYAD foi retirado da bolsa em 18 de maio de 2023.
Sobre: Celyad Oncology is a biopharmaceutical company, specialized in cell therapy. It develops technologies and treatments to treat severe diseases with poor prognosis. The company focuses on Immuno Oncology, Cardiology, and Medical devices. Its main product candidates include CAR-T and C-Cure. The firm has CYAD-01 and CYAD-02 programs in the pipeline. The company owns trademarks and service marks including CELYAD, C-CATH, C_CURE, CATH and C-CATHez and CARDIO 3 BIOSCIENCES. The firm has Cardiology and Immuno-oncology operating segments.
Funcionários: 39
Notícias
Positivo
Neutro
Negativo
Sentimento
3 meses
Positivo
0%
Neutro
0%
Negativo
0%
Não recebemos notícias recentes sobre CYAD
Gráficos de preços implementados com Lightweight Charts™